SLC7A5 and cancer: The anti-cancer potential of KYT-0353 or JHP203, a highly selective LAT1 inhibitor produced through synthetic chemistry and in vitro screening based on triiodothyronine (T3), has been reported in osteosarcoma [170], leukemic [171], oral cancer [172], gastric cancer [173], and colon cancer [173,174] cells, among others [157].